Portal de Periódicos da CAPES

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern

2022; American Society for Microbiology; Volume: 13; Issue: 4 Linguagem: Inglês

10.1128/mbio.01423-22

2161-2129

Bárbara M. Schultz, Felipe Melo-González, Luisa F. Duarte, Nicolás M. S. Gálvez, Gaspar A. Pacheco, Jorge A. Soto, Roslye V. Berríos-Rojas, Liliana A González, Daniela Moreno-Tapia, Daniela Rivera-Pérez, Mariana Ríos, Yaneisi Vázquez, Guillermo Hoppe-Elsholz, Catalina A. Andrade, Omar P. Vallejos, Alejandro Piña-Iturbe, Carolina Iturriaga, Marcela Urzúa, María S Navarrete, Álvaro Rojas, Rodrigo Fasce, Jorge Onrubia Fernández, Judith Mora, Eugenio Ramı́rez, Aracelly Gaete-Argel, Mónica L. Acevedo, Fernando Valiente‐Echeverría, Ricardo Soto‐Rifo, Daniela Weiskopf, Alba Grifoni, Alessandro Sette, Gang Zeng, Weining Meng, José Vicente González-Aramúndiz, Pablo A. González, Katia Abarca, Alexis M. Kalergis, Susan M. Bueno,

Vaccine Coverage and Hesitancy

CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 and 4 weeks after two doses of CoronaVac; these levels were significantly reduced at 6 to 8 months after the two doses. Here, we report the effect of a booster dose of CoronaVac on the anti-SARS-CoV-2 immune response generated against the variants of concern (VOCs), Delta and Omicron, in adults participating in a phase III clinical trial in Chile. Volunteers immunized with two doses of CoronaVac in a 4-week interval received a booster dose of the same vaccine between 24 and 30 weeks after the second dose. Neutralization capacities and T cell activation against VOCs Delta and Omicron were assessed 4 weeks after the booster dose. We observed a significant increase in neutralizing antibodies 4 weeks after the booster dose. We also observed a rise in anti-SARS-CoV-2-specific CD4